CR20230376A - Formulaciones de gel líquido concentradas que contienen sales de naproxeno - Google Patents

Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Info

Publication number
CR20230376A
CR20230376A CR20230376A CR20230376A CR20230376A CR 20230376 A CR20230376 A CR 20230376A CR 20230376 A CR20230376 A CR 20230376A CR 20230376 A CR20230376 A CR 20230376A CR 20230376 A CR20230376 A CR 20230376A
Authority
CR
Costa Rica
Prior art keywords
formulations containing
concentrated liquid
gel formulations
liquid gel
containing naproxen
Prior art date
Application number
CR20230376A
Other languages
English (en)
Inventor
Maluenda Blanca Alvarez
Saiz Maria Pilar Sanz
Pineiro Maria Elena Iglesias
Anthony Ekpe
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of CR20230376A publication Critical patent/CR20230376A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta descripción pertenece al campo de las minicápsulas blandas de gelatina, en particular cápsulas blandas de gelatina que contienen sal de naproxeno como ingrediente activo. Se refiere generalmente a cápsulas blandas de gelatina que contienen formulaciones de alta concentración de naproxeno sódico.
CR20230376A 2021-01-11 2022-01-10 Formulaciones de gel líquido concentradas que contienen sales de naproxeno CR20230376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135885P 2021-01-11 2021-01-11
PCT/US2022/070112 WO2022150848A1 (en) 2021-01-11 2022-01-10 Concentrated liquid gel formulations containing naproxen salts

Publications (1)

Publication Number Publication Date
CR20230376A true CR20230376A (es) 2023-12-12

Family

ID=82357519

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230376A CR20230376A (es) 2021-01-11 2022-01-10 Formulaciones de gel líquido concentradas que contienen sales de naproxeno

Country Status (9)

Country Link
US (2) US20240058274A1 (es)
EP (1) EP4274560A4 (es)
CA (1) CA3207235A1 (es)
CO (1) CO2023009202A2 (es)
CR (1) CR20230376A (es)
EC (1) ECSP23051920A (es)
MX (1) MX2023008192A (es)
PE (1) PE20240231A1 (es)
WO (1) WO2022150848A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341521B1 (en) * 2000-11-20 2009-01-07 Elan Pharma International Limited Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
US9504656B2 (en) * 2013-10-21 2016-11-29 Banner Life Sciences, LLC Pharmaceutical compositions for poorly soluble active ingredients
CN106413717A (zh) * 2014-04-10 2017-02-15 查尔斯顿实验室公司 药物组合物
WO2015195989A1 (en) * 2014-06-20 2015-12-23 Banner Life Sciences Llc Enteric soft capsule compositions
CA2910865C (en) * 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CR20200552A (es) * 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
AU2019362883B2 (en) * 2018-10-16 2025-07-31 Bayer Healthcare Llc Softgels with solid or gel-like polymeric fill matrix

Also Published As

Publication number Publication date
CA3207235A1 (en) 2022-07-14
MX2023008192A (es) 2023-07-18
EP4274560A1 (en) 2023-11-15
US20240041778A1 (en) 2024-02-08
ECSP23051920A (es) 2023-08-31
WO2022150848A1 (en) 2022-07-14
PE20240231A1 (es) 2024-02-16
US20240058274A1 (en) 2024-02-22
EP4274560A4 (en) 2024-12-25
CO2023009202A2 (es) 2023-07-31

Similar Documents

Publication Publication Date Title
CL2020002695A1 (es) Péptidos macrocíclicos contra actinetobacter baumannii
CL2015000574A1 (es) Formulaciones acuosas estables de adalimumab.
BR112017019696A2 (pt) composto e usos de um composto
AR083034A1 (es) ESTABILIZACION DE INMUNOGLOBULINAS Y OTRAS PROTEINAS MEDIANTE UNA FORMULACION ACUOSA CON CLORURO DE SODIO A pH ACIDO DEBIL A NEUTRO
PE20080310A1 (es) Formulaciones pobres en espuma para proteccion de las plantas
MX370903B (es) Composiciones de ácido percarboxílico estables y sus usos.
AR077839A1 (es) Formulaciones herbicidas de auxina con baja volatibilidad
GT200500132A (es) Formulaciones acuosas concentradas para la proteccion de las plantas
AR105798A2 (es) Preparaciones farmacéuticas para la aplicación oral, que contienen resinas intercambiadoras de iones cargadas con el producto activo, así como formadores de gel intrínsicamente viscosos a modo de espesantes
BR112021017924A2 (pt) 3-fenilisoxazolina-5-carboxamidas herbicidamente ativas de ésteres de ácido ciclopentenil- carboxílico contendo s
MX2022007399A (es) Variantes de alfa-glucosidasa ácida diseñadas.
AR084567A1 (es) Implante con calcio en su superficie y metodos de modificacion de la superficie de un implante para dotar a dicha superficie de calcio
BR112015002390A8 (pt) derivados do ácido 5-aminolevulínico (5-ala), sua composição e seu uso como agentes fotossensibilizantes
CL2016002000A1 (es) Agente y método de control para podredumbre blanda (divisional de sol. n° 220-13).
MX2015008529A (es) Solucion para conservar conductos vasculares.
RU2013129856A (ru) Способ количественного определения доз дезинфицирующего уф-излучения при помощи индикаторов
AR076932A1 (es) Formulaciones de n-halamina con actividad antimicrobiana aumentada. comprimido desinfectante. metodo para desinfectar.
PY1717949A (es) Composiciones, kits y métodos para mantener la higiene de los párpados
PE20061402A1 (es) Suspoemulsiones del tipo de agua en aceite
CL2016001003A1 (es) Soluciones para incrementar la estabilidad y la vida útil de un órgano, y solución de conservación de tejido
CO2025011311A2 (es) Compuestos sustituidos de pirazolopirimidina y su uso médico
ECSP23051920A (es) Formulaciones de gel líquido concentradas que contienen sales de naproxeno
PE20130180A1 (es) Soluciones farmaceuticas orales que comprenden telbivudina
ECSP099251A (es) Formulaciones farmacéuticas
UY31055A1 (es) Sales antimicrobianas de aminoacido n-halogenado